In early-stage disease, the phase II coopERA study had demonstrated superior efficacy of giredestrant over aromatase inhibitors in terms of Ki67 (a proliferation biomarker) suppression in ER+ breast cancer (8, 44). The gene discussed is ESR1; the disease is breast cancer.